Tazemetostat

Drug Profile

Tazemetostat

Alternative Names: E-7438; EPZ-6438

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech
  • Class Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdoid tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma

Most Recent Events

  • 18 Jan 2017 Epizyme plans a phase I trial for Diffuse large cell lymphoma and Mantle Cell Lymphoma (Second-line therapy or greater) in USA (PO) (NCT03028103)
  • 03 Jan 2017 Epizyme plans a phase I trial for B-cell lymphoma (Monotherapy, Second-line therapy or greater) in United Kingdom (PO and IV) (NCT03010982)
  • 30 Dec 2016 Eisai plans a phase I trial for Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in Japan (PO, Tablet) (NCT03009344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top